Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States.
Casey Kar-Chan ChoongMark BelgerAlisa E KochKristin J MeyersVincent C MarconiHamed AbedtashDouglas FariesVenkatesh KrishnanPublished in: Advances in therapy (2022)
Hospitalized adult patients with COVID-19 who required supplemental oxygen and received dexamethasone did not have a survival benefit versus similar patients not receiving dexamethasone. The dexamethasone group was not associated with favorable responses for outcomes such as progression to death or mechanical ventilation and time to in-hospital death.
Keyphrases
- mechanical ventilation
- high dose
- low dose
- sars cov
- end stage renal disease
- coronavirus disease
- acute respiratory distress syndrome
- chronic kidney disease
- newly diagnosed
- intensive care unit
- ejection fraction
- prognostic factors
- peritoneal dialysis
- emergency department
- metabolic syndrome
- patient reported outcomes
- respiratory failure
- respiratory syndrome coronavirus
- adverse drug
- patient reported
- glycemic control